The Stockholm Stock Exchange closed lower on Monday as market participants remained focused on developments in the Middle East.

According to reports from Axios, Iran has submitted a new proposal to the U.S. regarding the reopening of the Strait of Hormuz and an end to the conflict, with nuclear negotiations deferred to a later stage. Oil prices trended higher during the session.

On the domestic front, the earnings calendar was significantly quieter today ahead of the heavy reporting schedule expected on Tuesday and Wednesday. The news flow was highlighted by a takeover bid for Cint.

At the close, the OMXS30 index was down 0.69 percent at 3,079.76. Adjusted for dividends, the OMXS30 index declined by 0.63 percent. Shares worth approximately SEK 21.1 billion were traded on the Stockholm Stock Exchange.

Energy was the best-performing major industrial sector, posting a gain of 3.02 percent. Conversely, technology lagged at the bottom of the spectrum, falling 1.27 percent.

Among the blue-chip stocks in the OMXS30 index, Nordea rose 0.6 percent while Handelsbanken A gained 0.4 percent. Boliden saw the weakest performance, dropping 3.3 percent, while Telia declined 2.9 percent.

The bidding consortium TriCarbs Bidco has launched a recommended cash offer for the consumer insights company Cint at SEK 5.60 per share. The offer price represents a 33 percent premium over Friday's closing price and values the company at just under SEK 2 billion. Cint also released its Q1 report, which showed an increase in EBITA to EUR 4.6 million from EUR 3.7 million, despite sales falling by just over 5 percent. The stock surged 32.3 percent.

Specialty steel company Alleima reported an adjusted operating profit of SEK 386 million for Q1 2026, nearly 7 percent higher than anticipated. CEO Göran Björkman described market developments as mixed during the quarter. Alleima shares fell 2.3 percent.

Biotech firm Cantargia reported early results from a clinical study of the antibody nadunolimab in the blood cancers MDS and AML. The treatment was well tolerated and demonstrated an acceptable safety profile. In a small high-risk MDS cohort, all evaluable patients achieved complete remission, according to preliminary data. Cantargia rose 2.8 percent.

Medical technology company RaySearch opened lower but reversed course after announcing an order in France for RayStation and RayCare. The order, placed by Institut Hartmann and received during the first quarter of 2026, marks the company's first RayCare deal in France. The stock rose 1.6 percent.

On the analyst front, SEB upgraded its recommendation on Humana to Buy from Hold, maintaining a target price of SEK 50. The stock rallied 11.4 percent.

SEB also upgraded Lifco to Buy (Hold) with a target price of SEK 340 (300). The stock fell 2.5 percent.

Real estate company Castellum received two downgrades: Pareto Securities lowered its rating to Hold (Buy), while SB1 Markets moved to Neutral (Buy). Both firms now have a target price of SEK 130. The stock retreated 1.7 percent.

Dagens Industri issued a Buy recommendation on Paradox, sending the stock up 3.6 percent.

Analyst firms ABG, DNB, Carnegie, Nordea, and SEB all lowered their ratings on Mycronic. All now hold a Hold recommendation, down from Buy. The stock fell 3.5 percent.

Pareto downgraded Nordnet to Hold from Buy. The stock declined 1.2 percent.

Kepler Cheuvreux lowered ABB to Hold from Buy. The stock retreated 0.6 percent.

Pareto downgraded HMS Networks to Hold from Buy. The stock fell 1 percent.

Pareto also lowered NCAB to Hold from Buy. The stock dropped 3 percent.